Paper32989604
Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy.
Huang S and 3 others. J Cancer Res Clin Oncol, 2020. Cited by 92 papers, by iCite.
Cite this record
ConductScience Library. Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy. Papers, record 32989604. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32989604
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics4
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Bispecific | Major topic |
| Antigens, Neoplasm | Major topic |
| Neoplasms | Major topic |
| Humans |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 765394 | H2020 Marie Skłodowska-Curie Actions | PubMed |
Source PubMed
References82
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 9317136 | Flexibility of human IgG subclasses. | J Immunol | 1997 | https://conductscience.org/library/papers/9317136 | PubMed |
| 2 | 27037412 | RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis. | Mol Cancer Ther | 2016 | https://conductscience.org/library/papers/27037412 | PubMed |
| 3 | 26374073 | FDA Approval: Blinatumomab. | Clin Cancer Res | 2015 | https://conductscience.org/library/papers/26374073 | PubMed |
| 4 | 28405494 | Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. | Oncoimmunology | 2017 | https://conductscience.org/library/papers/28405494 | PubMed |
| 5 | 29155426 | CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. | Nat Med | 2018 | https://conductscience.org/library/papers/29155426 | PubMed |
| 6 | 314668 | Monoclonal antibodies defining distinctive human T cell surface antigens. | Science | 1979 | https://conductscience.org/library/papers/314668 | PubMed |
| 7 | 19692680 | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19692680 | PubMed |
| 8 | 29743205 | Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia. | Mol Cancer Ther | 2018 | https://conductscience.org/library/papers/29743205 | PubMed |
| 9 | 12621007 | Pretargeted radioimmunotherapy of cancer: progress step by step. | J Nucl Med | 2003 | https://conductscience.org/library/papers/12621007 | PubMed |
| 10 | 32414908 | Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. | Cancer Discov | 2020 | https://conductscience.org/library/papers/32414908 | PubMed |
| 11 | 31685488 | MCLA-128 Fights NRG1 Fusion-Positive Cancers. | Cancer Discov | 2019 | https://conductscience.org/library/papers/31685488 | PubMed |
| 12 | 32006223 | Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors. | Clin Pharmacokinet | 2020 | https://conductscience.org/library/papers/32006223 | PubMed |
| 13 | 13729245 | Properties of the major component of a peptic digest of rabbit antibody. | Science | 1960 | https://conductscience.org/library/papers/13729245 | PubMed |
| 14 | 11597399 | EGFR and cancer prognosis. | Eur J Cancer | 2001 | https://conductscience.org/library/papers/11597399 | PubMed |
| 15 | 31442474 | Mechanisms of acquired tumor drug resistance. | Biochim Biophys Acta Rev Cancer | 2019 | https://conductscience.org/library/papers/31442474 | PubMed |
| 16 | 29192287 | Next generation antibody drugs: pursuit of the 'high-hanging fruit'. | Nat Rev Drug Discov | 2018 | https://conductscience.org/library/papers/29192287 | PubMed |
| 17 | 9231898 | Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. | J Mol Biol | 1997 | https://conductscience.org/library/papers/9231898 | PubMed |
| 18 | 31772172 | On-target restoration of a split T cell-engaging antibody for precision immunotherapy. | Nat Commun | 2019 | https://conductscience.org/library/papers/31772172 | PubMed |
| 19 | 27742718 | Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. | EMBO Mol Med | 2016 | https://conductscience.org/library/papers/27742718 | PubMed |
| 20 | 21613623 | Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. | Sci Transl Med | 2011 | https://conductscience.org/library/papers/21613623 | PubMed |
Cited by62
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 92 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42818194 | Bispecific GD2xB7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma. | bioRxiv | 2026 | https://conductscience.org/library/papers/42818194 | PubMed |
| 42200831 | Safety and Efficacy of Mosunetuzumab: Experience in the Hospital Cardinale Giovanni Panico. | Antibodies (Basel) | 2026 | https://conductscience.org/library/papers/42200831 | PubMed |
| 42115599 | The evolving global landscape of first-in-class oncology drug innovation. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42115599 | PubMed |
| 41898489 | ASGR2 and CLEC12A as Prognostically Relevant C-Type Lectin Hubs in Glioblastoma. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41898489 | PubMed |
| 41832248 | Next generation approaches in cancer immunotherapy targeting mechanisms beyond PD1 and PDL1. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41832248 | PubMed |
| 41709436 | Antibody-Antibiotic Conjugates: Mechanisms, Clinical Progress, and Next-Generation Strategies Against Multidrug-Resistant Bacterial Infections. | Microbiologyopen | 2026 | https://conductscience.org/library/papers/41709436 | PubMed |
| 41601637 | Dual function antibody targeting αvβ3 and PD-L1 provide a promising strategy for solid tumor therapy. | Front Immunol | 2025 | https://conductscience.org/library/papers/41601637 | PubMed |
| 41586193 | Advances in cancer immunotherapy: Strategies and innovations strategies for adoptive immunotherapy of cancer. | Iran J Basic Med Sci | 2025 | https://conductscience.org/library/papers/41586193 | PubMed |
| 41348261 | Advancing breast cancer treatment through dual targeting CAR T cell therapy. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41348261 | PubMed |
| 41211166 | Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunities. | Explor Target Antitumor Ther | 2025 | https://conductscience.org/library/papers/41211166 | PubMed |
| 41154706 | Bispecific Antibody and Antibody-Drug Conjugate as Novel Candidates for Treating Pancreatic Ductal Adenocarcinoma. | Biomolecules | 2025 | https://conductscience.org/library/papers/41154706 | PubMed |
| 41016975 | Immune-based cancer therapies: mechanistic insights, clinical progress, and future directions. | J Egypt Natl Canc Inst | 2025 | https://conductscience.org/library/papers/41016975 | PubMed |
| 40909165 | Advances of bispecific antibodies using/application in dermatology: a review. | Front Allergy | 2025 | https://conductscience.org/library/papers/40909165 | PubMed |
| 40565299 | Bispecific Antibodies in Solid Tumors: Advances and Challenges. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40565299 | PubMed |
| 40508128 | From Molecular Precision to Clinical Practice: A Comprehensive Review of Bispecific and Trispecific Antibodies in Hematologic Malignancies. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40508128 | PubMed |
| 40427532 | Bispecific Antibodies, Nanobodies and Extracellular Vesicles: Present and Future to Cancer Target Therapy. | Biomolecules | 2025 | https://conductscience.org/library/papers/40427532 | PubMed |
| 40352940 | Bispecific antibodies combined with chemotherapy in solid tumor treatment, the path forward? | Front Immunol | 2025 | https://conductscience.org/library/papers/40352940 | PubMed |
| 40155973 | Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools. | Biomark Res | 2025 | https://conductscience.org/library/papers/40155973 | PubMed |
| 40106158 | Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer. | BioDrugs | 2025 | https://conductscience.org/library/papers/40106158 | PubMed |
| 39990653 | Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence. | Int J Biol Sci | 2025 | https://conductscience.org/library/papers/39990653 | PubMed |
Genes27
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32989604
GET https://conductscience.org/api/papers/v1/32989604/references?page=2